Lewis Bender
Directeur Général chez INTENSITY THERAPEUTICS, INC.
Fortune : 10 M $ au 30/06/2024
Profil
Lewis H.
Bender is the founder of Intensity Therapeutics, Inc., a company founded in 2012, where he currently holds the titles of Chairman, President & Chief Executive Officer.
Prior to founding Intensity Therapeutics, Inc., Mr. Bender held the position of Chief Executive Officer & Director at Interleukin Genetics, Inc. from 2011 to 2012.
From 1993 to 2007, he served as President, CEO & Chief Technology Officer at Emisphere Technologies, Inc. In terms of education, Mr. Bender holds a graduate degree from the University of Pennsylvania, undergraduate and graduate degrees from the Massachusetts Institute of Technology, and an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INTENSITY THERAPEUTICS, INC.
14,73% | 31/05/2024 | 2 020 000 ( 14,73% ) | 10 M $ | 30/06/2024 |
Postes actifs de Lewis Bender
| Sociétés | Poste | Début |
|---|---|---|
| INTENSITY THERAPEUTICS, INC. | Directeur Général | 01/04/2012 |
Anciens postes connus de Lewis Bender
| Sociétés | Poste | Fin |
|---|---|---|
| INTERLEUKIN GENETICS, INC | Directeur Général | 23/08/2012 |
| EMISPHERE TECHNOLOGIES, INC. | Directeur Général | 01/12/2007 |
Formation de Lewis Bender
| University of Pennsylvania | Graduate Degree |
| Massachusetts Institute of Technology | Graduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| INTENSITY THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Interleukin Genetics, Inc.
 Interleukin Genetics, Inc. Pharmaceuticals: MajorHealth Technology Interleukin Genetics, Inc. engages in the marketing and development of proprietary genetic tests for chronic inflammatory diseases and health-related conditions focuses on metabolism and inflammation. The company was founded in 1986 and is headquartered in Waltham, MA. | Health Technology |
Emisphere Technologies, Inc.
 Emisphere Technologies, Inc. Pharmaceuticals: MajorHealth Technology Emisphere Technologies, Inc. is a commercial stage specialty pharmaceutical company, which engages in the development of new formulations of existing products and chemical entities, using Eligen Technology. Its product pipelines include eligen B12, eligen12.com, eligen B12 information, and purchase eligen B12. The company was founded in 1986 and is headquartered in Roseland, NJ. | Health Technology |
